Clinical Trials Logo
  1. Home
  2. Human Influenza
  3. NCT03572491

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Human Influenza Clinical Trial

Official title:
A Phase 3, an Open Clinical Trials to Evaluate Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults

Clinical Trial Summary

The study is Multicenter, phase 3, Open-Label trial that explored the preventive effectiveness, safety and immunogenicity of single dose a allantoic split inactivated seasonal influenza vaccine in healthy adults.

Clinical Trial Description

The study will include 2000 volunteers, 1,000 of whom will be vaccinated intramuscularly with a single dose of allantoic split inactivated seasonal influenza vaccine.

All participants will be observed for 6 months to evaluate the effectiveness of the vaccine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03572491
Study type Interventional
Source Research Institute for Biological Safety Problems
Contact
Status Completed
Phase Phase 3
Start date September 18, 2017
Completion date May 21, 2018
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01690637 - Panama and El Salvador Children's Oseltamivir Study Phase 4
Recruiting NCT04487041 - Tfh Dysfunction in HIV and Aging Phase 4
Completed NCT02387294 - Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents Phase 3
Completed NCT02600585 - Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults N/A
Completed NCT01511744 - Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine Phase 4
Completed NCT02398097 - Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects Phase 4
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT01677702 - Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization N/A
Active, not recruiting NCT01096225 - Immunogenicity Study of S-OIV H1N1 Influenza Vaccine N/A
Completed NCT00880659 - Bangladesh Secondary Transmission Handwashing Protocol Phase 2
Completed NCT01879540 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age Phase 2
Completed NCT01879553 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above Phase 2
Completed NCT01651104 - Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects Phase 2
Completed NCT01636102 - Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above Phase 2
Completed NCT03448705 - Safety of 4Fluart ID Suspension for Injection in Adult Subjects Phase 1
Completed NCT02478905 - Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting N/A
Recruiting NCT04431050 - Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
Completed NCT01568788 - Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine N/A
Completed NCT05155319 - Universal Influenza A Vaccine in Healthy Adults Phase 1
Completed NCT01880697 - Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above Phase 3